<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd"><id root="0376527b-3759-4798-89ac-bebb7f8b7984"/><code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/><title>These highlights do not include all the information needed to use PRODUCT A safely and effectively. See full prescribing information for PRODUCT A.<br/> <br/>PRODUCT A (zanamivir inhalation powder), for oral inhalation use<br/>Initial U.S. Approval: 1999</title><effectiveTime value="20180621"/><setId root="d7c3bcc3-0c0d-4068-fd80-88cf54a376ef"/><versionNumber value="26"/><author><time/><assignedEntity><representedOrganization><id extension="167380711" root="1.3.6.1.4.1.519.1"/><name>MAH-A</name><assignedEntity><assignedOrganization><assignedEntity><confidentialityCode code="B" codeSystem="2.16.840.1.113883.5.25"/><assignedOrganization><id extension="149372109" root="1.3.6.1.4.1.519.1"/><name>MAH-A</name></assignedOrganization><performance><actDefinition><code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance></assignedEntity><assignedEntity><confidentialityCode code="B" codeSystem="2.16.840.1.113883.5.25"/><assignedOrganization><id extension="383861593" root="1.3.6.1.4.1.519.1"/><name>Glaxo Wellcome Production</name></assignedOrganization><performance><actDefinition><code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C84386" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PARTICLE SIZE REDUCTION"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance></assignedEntity><assignedEntity><confidentialityCode code="B" codeSystem="2.16.840.1.113883.5.25"/><assignedOrganization><id extension="424738227" root="1.3.6.1.4.1.519.1"/><name>Glaxo Operations UK Ltd</name></assignedOrganization><performance><actDefinition><code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance></assignedEntity><assignedEntity><confidentialityCode code="B" codeSystem="2.16.840.1.113883.5.25"/><assignedOrganization><id extension="595295577" root="1.3.6.1.4.1.519.1"/><name>Glaxo Wellcome Manufacturing Pte Ltd</name></assignedOrganization><performance><actDefinition><code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance></assignedEntity><assignedEntity><confidentialityCode code="B" codeSystem="2.16.840.1.113883.5.25"/><assignedOrganization><id extension="985745028" root="1.3.6.1.4.1.519.1"/><name>Thermo Fisher Scientific Cork Limited</name></assignedOrganization><performance><actDefinition><code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance><performance><actDefinition><code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/><product><manufacturedProduct classCode="MANU"><manufacturedMaterialKind><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/></manufacturedMaterialKind></manufacturedProduct></product></actDefinition></performance></assignedEntity></assignedOrganization></assignedEntity></representedOrganization></assignedEntity></author><component><structuredBody><component><section><id root="92df9123-62d8-4d11-9ec2-9139f0d5cfaf"/><code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/><effectiveTime value="20160804"/><subject><manufacturedProduct><manufacturedProduct><code code="0173-0681" codeSystem="2.16.840.1.113883.6.69"/><name>PRODUCT A</name><formCode code="C42972" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER"/><asEntityWithGeneric><genericMedicine><name>zanamivir</name></genericMedicine></asEntityWithGeneric><ingredient classCode="ACTIB"><quantity><numerator unit="mg" value="5"/><denominator unit="1" value="1"/></quantity><ingredientSubstance><code code="L6O3XI777I" codeSystem="2.16.840.1.113883.4.9"/><name>ZANAMIVIR</name><activeMoiety><activeMoiety><code code="L6O3XI777I" codeSystem="2.16.840.1.113883.4.9"/><name>ZANAMIVIR</name></activeMoiety></activeMoiety></ingredientSubstance></ingredient><ingredient classCode="IACT"><ingredientSubstance><code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/><name>LACTOSE, UNSPECIFIED FORM</name></ingredientSubstance></ingredient><asContent><quantity><numerator unit="1" value="4"/><denominator value="1"/></quantity><containerPackagedProduct><code/><formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/><asContent><quantity><numerator unit="1" value="5"/><denominator value="1"/></quantity><containerPackagedProduct><code code="0173-0681-01" codeSystem="2.16.840.1.113883.6.69"/><formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/></containerPackagedProduct><subjectOf><marketingAct><code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/><statusCode code="active"/><effectiveTime><low value="19990922"/></effectiveTime></marketingAct></subjectOf></asContent></containerPackagedProduct><subjectOf><characteristic classCode="OBS"><code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/><value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/></characteristic></subjectOf></asContent></manufacturedProduct><subjectOf><approval><id extension="NDA021036" root="2.16.840.1.113883.3.150"/><code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/><author><territorialAuthority><territory><code code="USA" codeSystem="2.16.840.1.113883.5.28"/></territory></territorialAuthority></author></approval></subjectOf><subjectOf><marketingAct><code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/><statusCode code="active"/><effectiveTime><low value="19990922"/></effectiveTime></marketingAct></subjectOf><consumedIn><substanceAdministration><routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/></substanceAdministration></consumedIn></manufacturedProduct></subject></section></component><component><section ID="i4i_indications_id_39a45f1e-a278-443b-9353-b2515efbe3f2"><id root="0bc41f31-730f-45bd-ab6c-46efa558a262"/><code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/><title>1 INDICATIONS AND USAGE</title><effectiveTime value="20180621"/><excerpt><highlight><text><paragraph>PRODUCT A, an influenza virus neuraminidase inhibitor (NAI), is indicated for:</paragraph><paragraph><content styleCode="bold">Treatment of acute, uncomplicated influenza type A and B infections </content>in patients aged 7 years and older who have been symptomatic for no more than 2 days. (<linkHtml href="#i4i_section_id_3b5913b6-280f-4457-ab1f-e2ae08296262">1.1</linkHtml>)</paragraph><paragraph><content styleCode="bold">Prophylaxis of influenza</content> in patients aged 5 years and older. (<linkHtml href="#i4i_section_id_ddbdce9b-ca40-4d48-9c9f-f4046b8166e3">1.2</linkHtml>)</paragraph><paragraph><content styleCode="bold">Important Limitations of Use:</content></paragraph><paragraph><content styleCode="bold">Not recommended for treatment or prophylaxis of influenza in:</content></paragraph><list listType="unordered"><item><caption>•</caption>Individuals with underlying airways disease. (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)</item></list><paragraph><content styleCode="bold">Not proven effective for:</content></paragraph><list listType="unordered"><item><caption>•</caption>Treatment in individuals with underlying airways disease. (<linkHtml href="#i4i_section_id_6c09747e-b051-43c8-9c19-86ab75fce3c9">1.3</linkHtml>)</item><item><caption>•</caption>Prophylaxis in nursing home residents. (<linkHtml href="#i4i_section_id_6c09747e-b051-43c8-9c19-86ab75fce3c9">1.3</linkHtml>)</item></list><paragraph><content styleCode="bold">Not a substitute for annual influenza vaccination. (<linkHtml href="#i4i_section_id_6c09747e-b051-43c8-9c19-86ab75fce3c9">1.3</linkHtml>)</content></paragraph><paragraph><content styleCode="bold">Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use PRODUCT A. (<linkHtml href="#i4i_section_id_6c09747e-b051-43c8-9c19-86ab75fce3c9">1.3</linkHtml>)</content></paragraph></text></highlight></excerpt><component><section ID="i4i_section_id_3b5913b6-280f-4457-ab1f-e2ae08296262"><id root="186dcb90-9016-4d99-b28d-2362906a1bc5"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>1.1 Treatment of Influenza</title><text><paragraph>PRODUCT A (zanamivir) inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_ddbdce9b-ca40-4d48-9c9f-f4046b8166e3"><id root="f740ddfa-4f03-417e-acb0-3e15384afee3"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>1.2 Prophylaxis of Influenza</title><text><paragraph>PRODUCT A is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older.</paragraph></text><effectiveTime value="20131017"/></section></component><component><section ID="i4i_section_id_6c09747e-b051-43c8-9c19-86ab75fce3c9"><id root="24d81361-0c38-4a80-b7c3-fd3ca0e39a4a"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>1.3 Important Limitations of Use</title><text><list listType="unordered"><item><caption>•</caption>PRODUCT A is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)]</content>.</item><item><caption>•</caption>PRODUCT A has not been proven effective for treatment of influenza in individuals with underlying airways disease.</item><item><caption>•</caption>PRODUCT A has not been proven effective for prophylaxis of influenza in the nursing home setting.</item><item><caption>•</caption>PRODUCT A is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee.</item><item><caption>•</caption>Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use PRODUCT A.</item><item><caption>•</caption>There is no evidence for efficacy of zanamivir in any illness caused by agents other than influenza virus A and B.</item><item><caption>•</caption>Patients should be advised that the use of PRODUCT A for treatment of influenza has not been shown to reduce the risk of transmission of influenza to others.</item></list></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_dosage_admin_id_a8cea56b-ab9f-41cf-9551-0c15530e94e1"><id root="7b411671-f33f-4a77-a634-e5dae3593484"/><code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/><title>2 DOSAGE AND ADMINISTRATION</title><effectiveTime value="20180621"/><excerpt><highlight><text><table width="100%"><col width="49%"/><col width="51%"/><tbody><tr><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Indication</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Dose</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Treatment of Influenza (<linkHtml href="#i4i_section_id_a83ac7ef-31b1-4867-9c02-093665593ed1">2.2</linkHtml>)</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>10 mg twice daily for 5 days</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>Prophylaxis: (<linkHtml href="#i4i_section_id_b4f8c2db-31df-4ad8-aba1-523da619f5c4">2.3</linkHtml>)</paragraph></td><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Household Setting</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>10 mg once daily for 10 days</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>   Community Outbreaks</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>10 mg once daily for 28 days</paragraph></td></tr></tbody></table><paragraph><content styleCode="bold">Note:</content> The 10-mg dose is provided by 2 inhalations (one 5-mg blister per inhalation). (<linkHtml href="#i4i_section_id_b970323a-5dc5-4466-afb7-b2a15078d07d">2.1</linkHtml>)</paragraph></text></highlight></excerpt><component><section ID="i4i_section_id_b970323a-5dc5-4466-afb7-b2a15078d07d"><id root="2f4caafe-a176-4c90-bb68-4999d0d3d14e"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>2.1 Dosing Considerations</title><text><list listType="unordered"><item><caption>•</caption>PRODUCT A is for administration to the respiratory tract by <content styleCode="italics">oral inhalation only</content>, using the DISKHALER device provided <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_170207b0-c24e-4cce-b41a-8fa670125188">5.6</linkHtml>)]</content>.</item><item><caption>•</caption>The 10-mg dose is provided by 2 inhalations (one 5-mg blister per inhalation).</item><item><caption>•</caption>Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible. If PRODUCT A is prescribed for children, it should be used only under adult supervision and instruction, and the supervising adult should first be instructed by a healthcare professional <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#i4i_info_patients_id_c146070e-3dcb-479d-8314-45aa492924bd">17</linkHtml>)]</content>.</item><item><caption>•</caption>Patients scheduled to use an inhaled bronchodilator at the same time as PRODUCT A should use their bronchodilator before taking PRODUCT A <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#i4i_info_patients_id_c146070e-3dcb-479d-8314-45aa492924bd">17</linkHtml>)]</content>.</item></list></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_a83ac7ef-31b1-4867-9c02-093665593ed1"><id root="cddd03eb-1663-47c6-8803-7ae91854d095"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>2.2 Treatment of Influenza</title><text><list listType="unordered"><item><caption>•</caption>The recommended dose of PRODUCT A for treatment of influenza in adults and pediatric patients aged 7 years and older is 10 mg twice daily (approximately 12 hours apart) for 5 days.</item><item><caption>•</caption>Two doses should be taken on the first day of treatment whenever possible provided there is at least 2 hours between doses.</item><item><caption>•</caption>On subsequent days, doses should be about 12 hours apart (e.g., morning and evening) at approximately the same time each day.</item><item><caption>•</caption>The safety and efficacy of repeated treatment courses have not been studied.</item></list></text><effectiveTime value="20131017"/></section></component><component><section ID="i4i_section_id_b4f8c2db-31df-4ad8-aba1-523da619f5c4"><id root="4e6ba4a3-a21b-4faa-b783-6d6423cdb80c"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>2.3 Prophylaxis of Influenza</title><text><paragraph><content styleCode="underline">Household Setting</content></paragraph><list listType="unordered"><item><caption>•</caption>The recommended dose of PRODUCT A for prophylaxis of influenza in adults and pediatric patients aged 5 years and older in a household setting is 10 mg once daily for 10 days.</item><item><caption>•</caption>The dose should be administered at approximately the same time each day.</item><item><caption>•</caption>There are no data on the effectiveness of prophylaxis with PRODUCT A in a household setting when initiated more than 1.5 days after the onset of signs or symptoms in the index case.</item></list><paragraph><content styleCode="underline">Community Outbreaks</content></paragraph><list listType="unordered"><item><caption>•</caption>The recommended dose of PRODUCT A for prophylaxis of influenza in adults and adolescents in a community setting is 10 mg once daily for 28 days.</item><item><caption>•</caption>The dose should be administered at approximately the same time each day. </item><item><caption>•</caption>There are no data on the effectiveness of prophylaxis with PRODUCT A in a community outbreak when initiated more than 5 days after the outbreak was identified in the community.</item><item><caption>•</caption>The safety and effectiveness of prophylaxis with PRODUCT A have not been evaluated for longer than 28 days’ duration.</item></list></text><effectiveTime value="20160804"/></section></component></section></component><component><section ID="i4i_dosage_form_strength_id_0ba6075b-27df-453c-90bc-7c32c96c8ffc"><id root="de58eaf7-7f3c-44e1-9cb3-e700ef6ae1a1"/><code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/><title>3 DOSAGE FORMS AND STRENGTHS</title><text><paragraph>Blister for oral inhalation: 5 mg. Four 5-mg blisters of powder on a ROTADISK for oral inhalation via DISKHALER. Packaged in carton containing 5 ROTADISKs (total of 10 doses) and 1 DISKHALER inhalation device <content styleCode="italics">[see How Supplied/Storage and Handling (<linkHtml href="#i4i_how_supplied_id_8af0c156-f6aa-4be6-b132-42f1799a8b61">16</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/><excerpt><highlight><text><paragraph>Blister for oral inhalation: 5 mg. Four 5-mg blisters of powder on a ROTADISK for oral inhalation via DISKHALER. Packaged in carton containing 5 ROTADISKs (total of 10 doses) and 1 DISKHALER inhalation device. (<linkHtml href="#i4i_dosage_form_strength_id_0ba6075b-27df-453c-90bc-7c32c96c8ffc">3</linkHtml>)</paragraph></text></highlight></excerpt></section></component><component><section ID="i4i_contraindications_id_fab9703d-a64a-4864-a899-3b4bbe9a1bf6"><id root="f9cd3833-5c6b-44b9-8099-cd97457b4cc6"/><code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/><title>4 CONTRAINDICATIONS</title><text><paragraph>PRODUCT A is contraindicated in patients with history of allergic reaction to any ingredient of PRODUCT A, including milk proteins<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#i4i_section_id_ba0ca588-40ac-4ccc-b93f-47c24ffd7378">5.2</linkHtml>), Description (<linkHtml href="#i4i_description_id_7c1593b2-ac9d-4ed5-9e7b-7ece51116666">11</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/><excerpt><highlight><text><paragraph>Do not use in patients with history of allergic reaction to any ingredient of PRODUCT A, including milk proteins. (<linkHtml href="#i4i_contraindications_id_fab9703d-a64a-4864-a899-3b4bbe9a1bf6">4</linkHtml>)</paragraph></text></highlight></excerpt></section></component><component><section ID="i4i_warnings_precautions_id_093fddfe-a0de-4c94-92ad-4b5c0c4283ec"><id root="397ba32b-6fed-418a-b631-ab56808c8f62"/><code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/><title>5 WARNINGS AND PRECAUTIONS</title><effectiveTime value="20180621"/><excerpt><highlight><text><list listType="unordered"><item><caption>•</caption><content styleCode="bold">Bronchospasm:</content> Serious, sometimes fatal, cases have occurred. Not recommended in individuals with underlying airways disease. Discontinue PRODUCT A if bronchospasm or decline in respiratory function develops. (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)</item><item><caption>•</caption><content styleCode="bold">Allergic Reactions:</content> Discontinue PRODUCT A and initiate appropriate treatment if an allergic reaction occurs or is suspected. (<linkHtml href="#i4i_section_id_ba0ca588-40ac-4ccc-b93f-47c24ffd7378">5.2</linkHtml>)</item><item><caption>•</caption><content styleCode="bold">Neuropsychiatric Events:</content> Patients with influenza, particularly pediatric patients, may be at an increased risk of seizures, confusion, or abnormal behavior early in their illness. Monitor for signs of abnormal behavior. (<linkHtml href="#i4i_section_id_3de8b6a5-8f12-4b25-a8d2-95169f34b8e6">5.3</linkHtml>)</item><item><caption>•</caption><content styleCode="bold">High-Risk Underlying Medical Conditions:</content> Safety and effectiveness have not been demonstrated in these patients. (<linkHtml href="#i4i_section_id_bae3af87-90c3-4fbc-aa38-97b62e5a9c60">5.4</linkHtml>)</item></list></text></highlight></excerpt><component><section ID="i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad"><id root="1f8578df-28d4-430c-8e34-454f0070d9e7"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.1 Bronchospasm</title><text><paragraph>PRODUCT A is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease).</paragraph><paragraph>Serious cases of bronchospasm, including fatalities, have been reported during treatment with PRODUCT A in patients with and without underlying airways disease. Many of these cases were reported during postmarketing and causality was difficult to assess.</paragraph><paragraph>PRODUCT A should be discontinued in any patient who develops bronchospasm or decline in respiratory function; immediate treatment and hospitalization may be required.</paragraph><paragraph>Some patients without prior pulmonary disease may also have respiratory abnormalities from acute respiratory infection that could resemble adverse drug reactions or increase patient vulnerability to adverse drug reactions.</paragraph><paragraph>Bronchospasm was documented following administration of zanamivir in 1 of 13 subjects with mild or moderate asthma (but without acute influenza‑like illness) in a Phase 1 trial. In a Phase 3 trial in subjects with acute influenza‑like illness superimposed on underlying asthma or chronic obstructive pulmonary disease, 10% (24 of 244) of subjects on zanamivir and 9% (22 of 237) on placebo experienced a greater than 20% decline in FEV<sub>1</sub> following treatment for 5 days.</paragraph><paragraph>If use of PRODUCT A is considered for a patient with underlying airways disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe PRODUCT A for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_ba0ca588-40ac-4ccc-b93f-47c24ffd7378"><id root="f0033397-0530-4dcb-8113-f40708236c19"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.2 Allergic Reactions</title><text><paragraph>Allergic-like reactions, including oropharyngeal edema, serious skin rashes, and anaphylaxis have been reported in postmarketing experience with PRODUCT A. PRODUCT A should be stopped and appropriate treatment instituted if an allergic reaction occurs or is suspected.</paragraph></text><effectiveTime value="20131017"/></section></component><component><section ID="i4i_section_id_3de8b6a5-8f12-4b25-a8d2-95169f34b8e6"><id root="5601ed52-a29f-47d9-94c9-7a0bf437fcff"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.3 Neuropsychiatric Events</title><text><paragraph>Influenza can be associated with a variety of neurologic and behavioral symptoms which can include events such as seizures, hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease.</paragraph><paragraph>There have been postmarketing reports of delirium and abnormal behavior leading to injury in patients with influenza who were receiving neuraminidase inhibitors (NAIs), including PRODUCT A. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon based on usage data for PRODUCT A. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of PRODUCT A to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior. If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated for each patient.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_bae3af87-90c3-4fbc-aa38-97b62e5a9c60"><id root="356e2dca-7894-492c-8876-5fa3e9d620ed"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.4 Limitations of Populations Studied</title><text><paragraph>Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions. No information is available regarding treatment of influenza in patients with any medical condition sufficiently severe or unstable to be considered at imminent risk of requiring inpatient management.</paragraph></text><effectiveTime value="20131017"/></section></component><component><section ID="i4i_section_id_3bf7e3d9-7205-4948-bec4-a998eda2ba28"><id root="c99f1ee3-53ee-46ce-96e7-0d4da4ade7a1"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.5 Bacterial Infections</title><text><paragraph>Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. PRODUCT A has not been shown to prevent such complications.</paragraph></text><effectiveTime value="20131017"/></section></component><component><section ID="i4i_section_id_170207b0-c24e-4cce-b41a-8fa670125188"><id root="7d0b6bcd-a6a9-442f-912a-67f469c19a34"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.6 Importance of Proper Route of Administration</title><text><paragraph>PRODUCT A inhalation powder must not be made into an extemporaneous solution for administration by nebulization or mechanical ventilation. There have been reports of hospitalized patients with influenza who received a solution made with PRODUCT A inhalation powder administered by nebulization or mechanical ventilation, including a fatal case where it was reported that the lactose in this formulation obstructed the proper functioning of the equipment. PRODUCT A inhalation powder must only be administered using the device provided <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_section_id_b970323a-5dc5-4466-afb7-b2a15078d07d">2.1</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_73386263-7d8c-414a-bb25-fb064e13408c"><id root="357c27c0-3132-4ff7-9ff8-a8eafbbaa081"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>5.7 Importance of Proper Use of DISKHALER</title><text><paragraph>Effective and safe use of PRODUCT A requires proper use of the DISKHALER to inhale the drug. Prescribers should carefully evaluate the ability of young children to use the delivery system if use of PRODUCT A is considered <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#i4i_pediatric_use_id_2f49ed46-aa35-4bb1-95ba-3641a5164d04">8.4</linkHtml>)].</content></paragraph></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_adverse_effects_id_f24b197d-74fb-449d-8489-22374e8befcd"><id root="c68a5835-bf75-4f1b-a474-313cd70aa968"/><code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/><title>6 ADVERSE REACTIONS</title><text><paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph><list listType="unordered"><item><caption>•</caption>Bronchospasm <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)]</content>.</item><item><caption>•</caption>Safety information in patients with underlying airways disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)].</content></item><item><caption>•</caption>Allergic-like reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_ba0ca588-40ac-4ccc-b93f-47c24ffd7378">5.2</linkHtml>)]</content>.</item></list></text><effectiveTime value="20180621"/><excerpt><highlight><text><paragraph>The most common adverse events reported in greater than 1.5% of subjects treated with PRODUCT A and more commonly than in subjects treated with placebo are:</paragraph><list listType="unordered"><item><caption>•</caption>Treatment Trials – sinusitis, dizziness. (<linkHtml href="#i4i_section_id_77b8db18-a110-4f94-b1c3-b1486375e769">6.1</linkHtml>)</item><item><caption>•</caption>Prophylaxis Trials – fever and/or chills, arthralgia, and articular rheumatism. (<linkHtml href="#i4i_section_id_77b8db18-a110-4f94-b1c3-b1486375e769">6.1</linkHtml>)</item></list><paragraph><content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact MAH-A.</content></paragraph></text></highlight></excerpt><component><section ID="i4i_section_id_77b8db18-a110-4f94-b1c3-b1486375e769"><id root="bcffd160-a447-4e19-8613-eb81b44c5477"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>6.1 Clinical Trials Experience</title><text><paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph><paragraph>The placebo used in clinical trials consisted of inhaled lactose powder, which is also the vehicle for the active drug; therefore, some adverse events occurring at similar frequencies in different treatment groups could be related to lactose vehicle inhalation.</paragraph><paragraph><content styleCode="underline">Treatment of Influenza</content></paragraph><paragraph><content styleCode="italics">Clinical Trials in Adults and Adolescents:</content> Adverse events that occurred with an incidence greater than or equal to 1.5% in treatment trials are listed in Table 1. This table shows adverse events occurring in subjects aged 12 years and older receiving PRODUCT A 10 mg inhaled twice daily, PRODUCT A in all inhalation regimens, and placebo inhaled twice daily (where placebo consisted of the same lactose vehicle used in PRODUCT A).</paragraph><table ID="_RefTOC_END" width="100%"><caption>Table 1. Summary of Adverse Events ≥1.5% Incidence during Treatment in Adults and Adolescents</caption><col width="34%"/><col width="33%"/><col width="16%"/><col width="17%"/><tfoot><tr><td align="left" colspan="4" styleCode="Botrule" valign="top"><sup>a</sup> Includes trials where PRODUCT A was administered intranasally (6.4 mg 2 to 4 times per day in addition to inhaled preparation) and/or inhaled more frequently (q.i.d.) than the currently recommended dose.</td></tr></tfoot><tbody><tr><td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">PRODUCT A</content></paragraph></td><td align="center" rowspan="2" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Placebo</content></paragraph><paragraph><content styleCode="bold">(Lactose Vehicle)</content></paragraph><paragraph><content styleCode="bold">(n = 1,520)</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">10 mg b.i.d. <content styleCode="underline">Inhaled</content></content></paragraph><paragraph><content styleCode="bold">(n = 1,132)</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="bottom"><paragraph><content styleCode="bold">All Dosing Regimens<sup>a</sup></content></paragraph><paragraph><content styleCode="bold">(n = 2,289)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Body as a whole</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Headaches</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Digestive</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Diarrhea</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nausea</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Vomiting</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Respiratory</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nasal signs and symptoms</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Bronchitis</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Cough</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Sinusitis</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Ear, nose, and throat infections</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Nervous system</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>   Dizziness</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>&lt;1%</paragraph></td></tr></tbody></table><paragraph>Additional adverse reactions occurring in less than 1.5% of subjects receiving PRODUCT A included malaise, fatigue, fever, abdominal pain, myalgia, arthralgia, and urticaria.</paragraph><paragraph>The most frequent laboratory abnormalities in Phase 3 treatment trials included elevations of liver enzymes and CPK, lymphopenia, and neutropenia. These were reported in similar proportions of zanamivir and lactose vehicle placebo recipients with acute influenza‑like illness.</paragraph><paragraph><content styleCode="italics">Clinical Trials in Pediatric Subjects:</content> Adverse events that occurred with an incidence greater than or equal to 1.5% in children receiving treatment doses of PRODUCT A in 2 Phase 3 trials are listed in <linkHtml href="#_Reftable_2">Table 2</linkHtml>. This table shows adverse events occurring in pediatric subjects aged 5 to 12 years receiving PRODUCT A 10 mg inhaled twice daily and placebo inhaled twice daily (where placebo consisted of the same lactose vehicle used in PRODUCT A).</paragraph><table ID="_Reftable_2" width="100%"><caption>Table 2. Summary of Adverse Events ≥1.5% Incidence during Treatment in Pediatric Subjects<sup>a</sup></caption><col width="46%"/><col width="29%"/><col width="25%"/><tfoot><tr><td align="left" colspan="7" styleCode="Botrule" valign="top"><sup>a</sup> Includes a subset of subjects receiving PRODUCT A for treatment of influenza in a prophylaxis trial.</td></tr></tfoot><tbody><tr><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">PRODUCT A</content></paragraph><paragraph><content styleCode="bold">10 mg b.i.d. Inhaled</content></paragraph><paragraph><content styleCode="bold">(n = 291)</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Placebo</content></paragraph><paragraph><content styleCode="bold">(Lactose Vehicle)</content></paragraph><paragraph><content styleCode="bold">(n = 318)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Respiratory</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Ear, nose, and throat infections</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Ear, nose, and throat hemorrhage</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>&lt;1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Asthma</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>&lt;1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Cough</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>&lt;1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Digestive</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Vomiting</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Diarrhea</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>   Nausea</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>&lt;1%</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2%</paragraph></td></tr></tbody></table><paragraph>In 1 of the 2 trials described in <linkHtml href="#_Reftable_2">Table 2</linkHtml>, some additional information is available from children (aged 5 to 12 years) without acute influenza-like illness who received an investigational prophylaxis regimen of PRODUCT A; 132 children received PRODUCT A and 145 children received placebo. Among these children, nasal signs and symptoms (zanamivir 20%, placebo 9%), cough (zanamivir 16%, placebo 8%), and throat/tonsil discomfort and pain (zanamivir 11%, placebo 6%) were reported more frequently with PRODUCT A than placebo. In a subset with chronic pulmonary disease, lower respiratory adverse events (described as asthma, cough, or viral respiratory infections which could include influenza-like symptoms) were reported in 7 of 7 zanamivir recipients and 5 of 12 placebo recipients.</paragraph><paragraph><content styleCode="underline">Prophylaxis of Influenza</content></paragraph><paragraph><content styleCode="italics">Family/Household Prophylaxis Trials:</content> Adverse events that occurred with an incidence of greater than or equal to 1.5% in the 2 prophylaxis trials are listed in <linkHtml href="#_Reftable_3">Table 3</linkHtml>. This table shows adverse events occurring in subjects aged 5 years and older receiving PRODUCT A 10 mg inhaled once daily for 10 days.</paragraph><table ID="_Reftable_3" width="100%"><caption>Table 3. Summary of Adverse Events ≥1.5% Incidence during 10-Day Prophylaxis Trials in Adults, Adolescents, and Children<sup>a</sup></caption><col width="40%"/><col width="39%"/><col width="20%"/><tfoot><tr><td align="left" colspan="10" styleCode="Botrule" valign="top"><sup>a</sup> In prophylaxis trials, symptoms associated with influenza-like illness were captured as adverse events; subjects were enrolled during a winter respiratory season during which time any symptoms that occurred were captured as adverse events.</td></tr></tfoot><tbody><tr><td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Contact Cases</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">PRODUCT A</content></paragraph><paragraph><content styleCode="bold">(n = 1,068)</content></paragraph></td><td align="center" styleCode="Rrule Botrule " valign="bottom"><paragraph><content styleCode="bold">Placebo</content></paragraph><paragraph><content styleCode="bold">(n = 1,059)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Lower respiratory</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Viral respiratory infections</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>13%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>19%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Cough</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>7%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>9%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Neurologic</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Headaches</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>13%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>14%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Ear, nose, and throat</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nasal signs and symptoms</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>12%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>12%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Throat and tonsil discomfort and pain</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>8%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>9%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nasal inflammation</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Musculoskeletal</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Muscle pain</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Endocrine and metabolic</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Feeding problems (decreased or increased appetite and anorexia)</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Gastrointestinal</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nausea and vomiting</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Non-site specific</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Malaise and fatigue</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>5%</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>   Temperature regulation disturbances (fever and/or chills)</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>4%</paragraph></td></tr></tbody></table><paragraph><content styleCode="italics">Community Prophylaxis Trials:</content> Adverse events that occurred with an incidence of greater than or equal to 1.5% in 2 prophylaxis trials are listed in <linkHtml href="#_Reftable_4">Table 4</linkHtml>. This table shows adverse events occurring in subjects aged 5 years and older receiving PRODUCT A 10 mg inhaled once daily for 28 days. </paragraph><table ID="_Reftable_4" width="100%"><caption>Table 4. Summary of Adverse Events ≥1.5% Incidence during 28-Day Prophylaxis Trials in Adults, Adolescents, and Children<sup>a</sup></caption><col width="52%"/><col width="24%"/><col width="24%"/><tfoot><tr><td align="left" colspan="13" styleCode="Botrule" valign="top"><sup>a</sup> In prophylaxis trials, symptoms associated with influenza-like illness were captured as adverse events; subjects were enrolled during a winter respiratory season during which time any symptoms that occurred were captured as adverse events.</td></tr></tfoot><tbody><tr><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Adverse Event</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">PRODUCT A</content></paragraph><paragraph><content styleCode="bold">(n = 2,231)</content></paragraph></td><td align="center" styleCode="Rrule Botrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Placebo</content></paragraph><paragraph><content styleCode="bold">(n = 2,239)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Neurologic</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Headaches</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>24%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>26%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Ear, nose, and throat</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Throat and tonsil discomfort and pain</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>19%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>20%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nasal signs and symptoms</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>12%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>13%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Ear, nose, and throat infections</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Lower respiratory</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Cough</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>17%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>18%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Viral respiratory infections</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Musculoskeletal</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Muscle pain</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>8%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>8%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Musculoskeletal pain</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>6%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>6%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Arthralgia and articular rheumatism</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>&lt;1%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Endocrine and metabolic</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Feeding problems (decreased or increased appetite and anorexia)</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>4%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Gastrointestinal</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Nausea and vomiting</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Diarrhea</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Non-site specific</content></paragraph></td><td styleCode="Rrule " valign="top"/><td styleCode="Rrule " valign="top"/></tr><tr><td styleCode="Rrule Lrule " valign="top"><paragraph>   Temperature regulation disturbances (fever and/or chills)</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>9%</paragraph></td><td align="center" styleCode="Rrule " valign="top"><paragraph>10%</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>   Malaise and fatigue</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>8%</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>8%</paragraph></td></tr></tbody></table></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_59026187-40e9-4b58-ae9f-3f39659b6291"><id root="8d1110ee-520e-4097-888f-b49e91af1e40"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>6.2 Postmarketing Experience</title><text><paragraph>The following adverse reactions have been identified during post-approval use of PRODUCT A. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph><paragraph><content styleCode="underline">Allergic Reactions</content></paragraph><paragraph>Allergic or allergic-like reaction, including oropharyngeal edema <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_ba0ca588-40ac-4ccc-b93f-47c24ffd7378">5.2</linkHtml>)]</content>.</paragraph><paragraph><content styleCode="underline">Psychiatric</content></paragraph><paragraph>Delirium, including symptoms such as altered level of consciousness, confusion, abnormal behavior, delusions, hallucinations, agitation, anxiety, nightmares <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_3de8b6a5-8f12-4b25-a8d2-95169f34b8e6">5.3</linkHtml>)].</content></paragraph><paragraph><content styleCode="underline">Cardiac</content></paragraph><paragraph>Arrhythmias, syncope.</paragraph><paragraph><content styleCode="underline">Neurologic</content></paragraph><paragraph>Seizures. Vasovagal-like episodes have been reported shortly following inhalation of zanamivir.</paragraph><paragraph><content styleCode="underline">Respiratory</content></paragraph><paragraph>Bronchospasm, dyspnea <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)]</content>.</paragraph><paragraph><content styleCode="underline">Skin</content></paragraph><paragraph>Facial edema; rash, including serious cutaneous reactions (e.g., erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis); urticaria <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_ba0ca588-40ac-4ccc-b93f-47c24ffd7378">5.2</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_interactions_id_f5a976f4-d9d0-42e0-bba3-98a277805ca4"><id root="e89bd83f-25f3-4846-bcd0-269cee9bb6f5"/><code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/><title>7 DRUG INTERACTIONS</title><text><paragraph>The concurrent use of PRODUCT A with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of potential interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of PRODUCT A, unless medically indicated. The concern about possible interference arises from the potential for antiviral drugs to inhibit replication of live vaccine virus.</paragraph><paragraph>Trivalent inactivated influenza vaccine can be administered at any time relative to use of PRODUCT A <content styleCode="italics">[see Microbiology (<linkHtml href="#i4i_section_id_46aae477-f4f7-4445-8bbf-38baf4efce97">12.4</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/><excerpt><highlight><text><paragraph>Live attenuated influenza vaccine, intranasal (<linkHtml href="#i4i_interactions_id_f5a976f4-d9d0-42e0-bba3-98a277805ca4">7</linkHtml>):</paragraph><list listType="unordered"><item><caption>•</caption>Do not administer until 48 hours following cessation of PRODUCT A.</item><item><caption>•</caption>Do not administer PRODUCT A until 2 weeks following administration of the live attenuated influenza vaccine, unless medically indicated.</item></list></text></highlight></excerpt></section></component><component><section ID="i4i_specific_populations_id_78218d59-938e-47d2-a66b-2d201b25001f"><id root="96d498bd-c490-46be-a2d5-5d5fe71d12b1"/><code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/><title>8 USE IN SPECIFIC POPULATIONS</title><effectiveTime value="20180621"/><component><section ID="i4i_pregnancy_id_cd9b134c-ee08-43f7-b9c1-c9cf363a717c"><id root="23372d88-59d9-4dd8-a67b-084de3020cbd"/><code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/><title>8.1 Pregnancy</title><text><paragraph><content styleCode="underline">Risk Summary</content></paragraph><paragraph>Available data from published studies suggest that use of PRODUCT A during pregnancy is not associated with an increased risk of birth defects or adverse maternal or fetal outcomes. However, these studies are limited by their small sample sizes, which preclude a definitive assessment of the risk <content styleCode="italics">(see Data).</content> There are risks to the mother and fetus associated with influenza infection in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. In animal reproduction studies, no adverse developmental effects were observed with intravenous or subcutaneous administration of zanamivir at exposures 300 and 150 times, respectively, the systemic exposure at the maximum recommended human inhalation dose (MRHID) of 10 mg twice daily <content styleCode="italics">(see Data)</content>. </paragraph><paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph><paragraph><content styleCode="underline">Clinical Considerations</content></paragraph><paragraph><content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk: </content>Pregnant women are at higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes, including maternal death, stillbirths, birth defects, preterm delivery, low birth weight, and small for gestational age.</paragraph><paragraph><content styleCode="underline">Data</content></paragraph><paragraph><content styleCode="italics">Human Data: </content>A study of population-based registers from Denmark, Norway, Sweden, and France reported outcomes of 5,824 pregnant women who filled a prescription for an NAI compared with outcomes in unexposed pregnant women in the general population. This study included 1,560 women who filled a prescription for zanamivir (including 321 first trimester exposures). Although no specific analyses were conducted for zanamivir, exposure to the NAI class in utero was not associated with major birth defects, preterm birth, low birth weight, small for gestational age, still birth, neonatal morbidity, or neonatal mortality.</paragraph><paragraph>A few published studies compared outcomes of pregnant women exposed to zanamivir with outcomes in various comparator cohorts. These studies suggested no increased risk of major birth defects, preterm birth, or low birth weight. Sample sizes in these studies ranged from 50 to 180 pregnant women exposed to zanamivir, including 15 to 44 women exposed in the first trimester. Limitations of available studies include the lack of specific analyses for zanamivir, possible exposure and outcome misclassification, and small sample sizes. These limitations preclude a definitive assessment of the risk.</paragraph><paragraph><content styleCode="italics">Animal Data:</content> Zanamivir was administered intravenously to pregnant rats and rabbits at 1, 9, or 90 mg/kg/day during organogenesis (gestation Day 6 to 15 [rat] and 7 to 19 [rabbit]). No adverse maternal or embryo-fetal effects were observed up to the highest intravenous dose of zanamivir (90 mg/kg/day), resulting in systemic drug exposure (AUC) estimated from both rats and rabbits, 300 times the exposure at the MRHID. In a separate study, zanamivir was administered subcutaneously to pregnant rats at 3, 27, and 240 mg/kg/day in three divided doses during organogenesis (gestation Day 7 to 17). An increased incidence of skeletal and visceral alterations and variants was observed at the high dose (240 mg/kg/day). No adverse maternal or embryo-fetal effects were observed at the middle dose (27 mg/kg/day), resulting in systemic drug exposure (AUC) 150 times the exposure at the MRHID.</paragraph><paragraph>In prenatal and postnatal development studies in rats, zanamivir was administered intravenously at 1, 9, or 90 mg/kg/day during organogenesis (gestation Day 0 to 19) or from late gestation through delivery and lactation (gestation Day 16 to post-partum/lactation Day 21). No significant effects were observed in the offspring at systemic drug exposures (AUC) estimated to be 300 times the exposure at the MRHID. </paragraph><paragraph>Zanamivir distributed across the placenta in pregnant rats and rabbits, with less than 0.04% of the administered maternal dose being recovered from the fetus on gestation Day 12. </paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_nursing_mothers_id_f2e45f03-d22f-4bcf-ae6c-26f3c9820151"><id root="824104f9-fce9-494f-8e2e-bd35a8f30ca3"/><code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/><title>8.2 Lactation</title><text><paragraph><content styleCode="underline">Risk Summary</content></paragraph><paragraph>There are no data on the presence of zanamivir in human milk or the effects on milk production. There are data from adults that have shown low oral bioavailability of zanamivir. Limited data from postmarketing case reports have not suggested a safety concern in infants exposed to breast milk of mothers using PRODUCT A. Zanamivir was present in the milk of lactating rats without effect on nursing pups <content styleCode="italics">(see Data)</content>. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PRODUCT A and any potential adverse effects on the breastfed child from PRODUCT A or the underlying maternal condition.</paragraph><paragraph><content styleCode="underline">Data</content></paragraph><paragraph>In a lactation study, zanamivir was excreted in the milk of lactating rats administered zanamivir intravenously (10 mg/kg) on post-partum/lactation Day 10, with peak milk concentrations of approximately 10% that of maternal plasma concentrations occurring 30 minutes post-dose. No effects of zanamivir on growth and postnatal development were observed in nursing pups at the highest intravenous dose tested in rats. Maternal systemic exposure (AUC) of zanamivir was approximately 300 times the exposure in humans at the MRHID. </paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_pediatric_use_id_2f49ed46-aa35-4bb1-95ba-3641a5164d04"><id root="7568a038-1dd7-4d28-9e3e-96a2c4d812d1"/><code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/><title>8.4 Pediatric Use</title><text><paragraph><content styleCode="underline">Treatment of Influenza</content></paragraph><paragraph>Safety and effectiveness of PRODUCT A for treatment of influenza have not been assessed in pediatric patients younger than 7 years, but were studied in a Phase 3 treatment trial in pediatric subjects, where 471 children aged 5 to 12 years received zanamivir or placebo <content styleCode="italics">[see Clinical Studies (<linkHtml href="#i4i_section_id_91a44324-678d-4752-8c32-73111782491a">14.1</linkHtml>)]</content>. Adolescents were included in the 3 principal Phase 3 adult treatment trials. In these trials, 67 patients were aged 12 to 16 years. No definite differences in safety and efficacy were observed between these adolescent patients and young adults.</paragraph><paragraph>In a Phase 1 trial of 16 children aged 6 to 12 years with signs and symptoms of respiratory disease, 4 did not produce a measurable peak inspiratory flow rate (PIFR) through the DISKHALER (3 with no adequate inhalation on request, 1 with missing data), 9 had measurable PIFR on each of 2 inhalations, and 3 achieved measurable PIFR on only 1 of 2 inhalations. Neither of two 6-year-olds and one of two 7-year-olds produced measurable PIFR. Overall, 8 of the 16 children (including all those younger than 8 years) either did not produce measurable inspiratory flow through the DISKHALER or produced peak inspiratory flow rates below the 60 L/minute considered optimal for the device under standardized in vitro testing; lack of measurable flow rate was related to low or undetectable serum concentrations <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_1d1feeae-4abe-476b-ad9f-42f65398336d">12.3</linkHtml>), Clinical Studies (<linkHtml href="#i4i_section_id_91a44324-678d-4752-8c32-73111782491a">14.1</linkHtml>)]</content>. Prescribers should carefully evaluate the ability of young children to use the delivery system if prescription of PRODUCT A is considered.</paragraph><paragraph><content styleCode="underline">Prophylaxis of Influenza</content></paragraph><paragraph>The safety and effectiveness of PRODUCT A for prophylaxis of influenza have been studied in 4 Phase 3 trials where 273 children aged 5 to 11 years and 239 adolescents aged 12 to 16 years received PRODUCT A. No differences in safety and effectiveness were observed between pediatric and adult subjects <content styleCode="italics">[see Clinical Studies (<linkHtml href="#i4i_section_id_58f0ac09-0968-446c-b72b-9d46d737f2b2">14.2</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_geriatric_use_id_1fdb4246-2b52-47dc-8fa5-832cc518db6d"><id root="41734b40-4e66-4fec-a7a3-9862d5116b0e"/><code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/><title>8.5 Geriatric Use</title><text><paragraph>Of the total number of subjects in 6 clinical trials of PRODUCT A for treatment of influenza, 59 subjects were aged 65 years and older, while 24 subjects were aged 75 years and older. Of the total number of subjects in 4 clinical trials of PRODUCT A for prophylaxis of influenza in households and community settings, 954 subjects were aged 65 years and older, while 347 subjects were aged 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. Elderly patients may need assistance with use of the device.</paragraph><paragraph>In 2 additional trials of PRODUCT A for prophylaxis of influenza in the nursing home setting, efficacy was not demonstrated <content styleCode="italics">[see Indications and Usage (<linkHtml href="#i4i_section_id_6c09747e-b051-43c8-9c19-86ab75fce3c9">1.3</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="ID_99645cf0-4933-40cf-b062-ce2cd9d41c42"><id root="6a112db0-0e13-4c65-81b8-616022c45d48"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>8.6 Renal Impairment </title><text><paragraph>Safety and efficacy have not been documented in the presence of severe renal insufficiency. Due to the low systemic bioavailability of zanamivir following oral inhalation, no dosage adjustments are necessary in patients with renal impairment. However, the potential for drug accumulation should be considered.</paragraph></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_overdosage_id_7900a4c5-a13a-4177-abfc-37be07317167"><id root="df5e9dd8-e591-4049-a7cf-5d2f7020f1f6"/><code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/><title>10 OVERDOSAGE</title><text><paragraph>Reports of overdosage from administration of PRODUCT A have been received during postmarketing experience. The reported clinical signs or symptoms were similar to those observed with therapeutic doses of PRODUCT A and the underlying disease.</paragraph><paragraph>As zanamivir has a low molecular weight, low protein binding, and small volume of distribution, it is expected to be removed by hemodialysis.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_description_id_7c1593b2-ac9d-4ed5-9e7b-7ece51116666"><id root="f60ba57d-1707-4d0e-a68e-7984c3f02787"/><code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/><title>11 DESCRIPTION</title><text><paragraph>The active component of PRODUCT A is zanamivir. The chemical name of zanamivir is 5-(acetylamino)-4-[(aminoiminomethyl)-amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid. It has a molecular formula of C<sub>12</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7 </sub>and a molecular weight of 332.3. It has the following structural formula:</paragraph><renderMultiMedia ID="id1018" referencedObject="ID_38d08a97-9174-42b0-9645-6f260ba1363a"/><paragraph>Zanamivir is a white to off-white powder for oral inhalation with a solubility of approximately 18 mg/mL in water at 20°C.</paragraph><paragraph>PRODUCT A is for administration to the respiratory tract by oral inhalation only. Each PRODUCT A ROTADISK contains 4 regularly spaced double-foil blisters with each blister containing a powder mixture of 5 mg of zanamivir and 20 mg of lactose (which contains milk proteins). The contents of each blister are inhaled using a specially designed breath-activated plastic device for inhaling powder called the DISKHALER. After a PRODUCT A ROTADISK is loaded into the DISKHALER, a blister that contains medication is pierced and the zanamivir is dispersed into the air stream created when the patient inhales through the mouthpiece. The amount of drug delivered to the respiratory tract will depend on patient factors such as inspiratory flow. Under standardized in vitro testing, PRODUCT A ROTADISK delivers 4 mg of zanamivir from the DISKHALER device when tested at a pressure drop of 3 kPa (corresponding to a flow rate of about 62 to 65 L/minute) for 3 seconds.</paragraph></text><effectiveTime value="20180621"/><component><observationMedia ID="ID_38d08a97-9174-42b0-9645-6f260ba1363a"><text>zanamivir structural formula</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-01.jpg"/></value></observationMedia></component></section></component><component><section ID="i4i_clinical_pharmacology_id_6ec39e09-f5ae-418a-a0da-0880456f59cf"><id root="8ebe9b5a-3a85-415f-875e-3bad80fefd56"/><code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/><title>12 CLINICAL PHARMACOLOGY</title><effectiveTime value="20180621"/><component><section ID="i4i_mechanism_action_id_52d21d1f-fbef-487a-96ec-1dd495e6161c"><id root="0e83cad3-5910-41e7-97cc-24fdf7c395e6"/><code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/><title>12.1 Mechanism of Action</title><text><paragraph>Zanamivir is an antiviral drug with activity against influenza virus <content styleCode="italics">[see Microbiology (<linkHtml href="#i4i_section_id_46aae477-f4f7-4445-8bbf-38baf4efce97">12.4</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="ID_a4eaf38c-a642-46b2-97ea-3aa8c8d8b238"><id root="829a93a4-b0ab-4c68-9abd-b6c73e71f221"/><code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/><title>12.2 Pharmacodynamics </title><text><paragraph><content styleCode="underline">Cardiac Electrophysiology</content></paragraph><paragraph>In a thorough QT/QTc study in 40 healthy subjects, intravenous zanamivir 600 mg and 1,200 mg (60 and 120 times the dose in PRODUCT A) had no effect on the QTc interval and did not prolong the PR interval.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_pharmacokinetics_id_1d1feeae-4abe-476b-ad9f-42f65398336d"><id root="0ca7dfb2-9f7f-49eb-828d-933a779bdc4b"/><code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/><title>12.3 Pharmacokinetics</title><text><paragraph><content styleCode="underline">Absorption and Bioavailability</content></paragraph><paragraph>Pharmacokinetic studies of orally inhaled zanamivir indicate that approximately 4% to 17% of the inhaled dose is systemically absorbed. The peak serum concentrations ranged from 17 to 142 ng/mL within 1 to 2 hours following a 10‑mg dose. The area under the serum concentration versus time curve (AUC∞) ranged from 111 to 1,364 ng•hour/mL.</paragraph><paragraph><content styleCode="underline">Distribution</content></paragraph><paragraph>Zanamivir plasma protein binding is less than 10% and the blood to plasma ratio is 0.56. The volume of distribution is approximately 16 L. The 2 major sites of deposition are the oropharynx and the lungs (mean 77.6% and 13.2%, respectively). </paragraph><paragraph><content styleCode="underline">Elimination</content></paragraph><paragraph>The serum half‑life of zanamivir following administration by oral inhalation ranges from 2.5 to 5.1 hours.</paragraph><paragraph><content styleCode="italics">Metabolism:</content> No metabolites have been detected in humans.</paragraph><paragraph><content styleCode="italics">Excretion:</content> Zanamivir is eliminated by renal filtration with excretion of a single dose completed within 24 hours. Total clearance ranges from 2.5 to 10.9 L/hour. Unabsorbed drug is excreted in the feces.</paragraph><paragraph><content styleCode="underline">Specific Populations</content></paragraph><paragraph><content styleCode="italics">Patients with Hepatic Impairment:</content> The pharmacokinetics of zanamivir have not been studied in patients with impaired hepatic function.</paragraph><paragraph><content styleCode="italics">Patients with Renal Impairment:</content> After a single intravenous dose of 4 mg or 2 mg of zanamivir in volunteers with renal impairment determined by the Cockcroft and Gault method, significant increases in systemic exposure were observed (<linkHtml href="#_Reftable_5">Table 5</linkHtml>). </paragraph><table ID="_Reftable_5" width="100%"><caption>Table 5. Zanamivir Exposure in Subjects with Renal Impairment Compared with Healthy Subjects</caption><col width="23%"/><col width="25%"/><col width="27%"/><col width="25%"/><tfoot><tr><td align="left" colspan="4" styleCode="Botrule" valign="top"><sup>a</sup>  Geometric mean (95% confidence interval)<br/>C<sub>max</sub> = Maximum serum concentration; AUC<sub>0-inf</sub> = Area under the serum concentration-time curve from zero to infinity; CrCl = Creatinine Clearance.</td></tr></tfoot><tbody><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="top"/><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">CrCl &gt;70 mL/min</content><br/><content styleCode="bold">(n = 7)</content></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">CrCl = 25-70 mL/min</content><br/><content styleCode="bold">(n = 5)</content></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">CrCl &lt;25 mL/min</content><br/><content styleCode="bold">(n = 5)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>C<sub>max</sub> (ng/mL)<sup>a</sup></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>257 (182, 363)</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>316 (234, 427)</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>202 (141, 289)</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>AUC<sub>0-inf </sub>(ng∙h/mL)<sup>a</sup></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>737 (567, 957)</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>1,519 (1181, 1954)</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>2,587 (1514, 4419)</paragraph></td></tr></tbody></table><paragraph><content styleCode="italics">Pediatric Patients:</content> The pharmacokinetics of zanamivir were evaluated in pediatric subjects with signs and symptoms of respiratory illness. Sixteen subjects, aged 6 to 12 years, received a single dose of 10 mg zanamivir dry powder via DISKHALER. Five subjects had either undetectable zanamivir serum concentrations or had low drug concentrations (8.32 to 10.38 ng/mL) that were not detectable after 1.5 hours. Eleven subjects had C<sub>max</sub> median values of 43 ng/mL (range: 15 to 74) and AUC∞ median values of 167 ng•hour/mL (range: 58 to 279). Low or undetectable serum concentrations were related to lack of measurable PIFR in individual subjects <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#i4i_pediatric_use_id_2f49ed46-aa35-4bb1-95ba-3641a5164d04">8.4</linkHtml>), Clinical Studies (<linkHtml href="#i4i_section_id_91a44324-678d-4752-8c32-73111782491a">14.1</linkHtml>)]</content>.</paragraph><paragraph><content styleCode="italics">Geriatric Patients:</content> The pharmacokinetics of zanamivir have not been studied in subjects older than 65 years <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#i4i_geriatric_use_id_1fdb4246-2b52-47dc-8fa5-832cc518db6d">8.5</linkHtml>)]</content>.</paragraph><paragraph><content styleCode="italics">Gender, Race, and Weight:</content> There were no clinically significant pharmacokinetic changes associated with gender, race, or weight. </paragraph><paragraph><content styleCode="underline">Drug Interaction Studies</content></paragraph><paragraph>Zanamivir is not a substrate of cytochrome P450 (CYP) isoenzymes or P-glycoprotein (P-gp), does not inhibit renal transporters OAT1-4, OCT1-3, or URAT1, and does not inhibit CYP isoenzymes CYP1A1/2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in human liver microsomes. </paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_46aae477-f4f7-4445-8bbf-38baf4efce97"><id root="de71cc1b-fe39-459b-bc06-3a1e013bd55f"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>12.4 Microbiology</title><text><paragraph><content styleCode="underline">Mechanism of Action</content></paragraph><paragraph>Zanamivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and promotes virus spread in the respiratory tract. In neuraminidase inhibition assays, zanamivir is active against all neuraminidase (NA) enzyme subtypes N1 to N9. The median baseline 50% neuraminidase inhibitory concentrations (IC<sub>50</sub>) of zanamivir for influenza type A subtype H1N1, influenza type A subtype H3N2, and influenza type B viruses were 0.85 nM (n = 31; range: 0.45 to 1.35 nM), 1.01 nM (n = 32; range: 0.33 to 2.04 nM), and 3.86 nM (n = 16; range: 2.02 to 5.77 nM), respectively, in a chemiluminescent assay. Amino acid substitutions have been found in the neuraminidase active site that reduce virus susceptibility to zanamivir <content styleCode="italics">(see Resistance)</content>.</paragraph><paragraph><content styleCode="underline">Antiviral Activity</content></paragraph><paragraph>Zanamivir has been demonstrated to inhibit laboratory and clinical isolates of influenza virus in cell culture. The median EC<sub>50</sub> values of zanamivir in cell culture assays for influenza type A (subtypes H1N1 and H3N2) and influenza type B viruses were 210 nM (70 ng/mL) (n = 10; range: 1 to 16,000 nM), 14 nM (4.7 ng/mL) (n = 12; range: 1 to 1,700 nM), and 18 nM (6 ng/mL) (n = 9; range: 3 to 1,300 nM), respectively. The relationship between the cell culture inhibition of influenza virus by zanamivir and the inhibition of influenza virus replication in humans has not been established.</paragraph><paragraph><content styleCode="underline">Resistance</content></paragraph><paragraph><content styleCode="italics">Cell Culture:</content> Influenza viruses with reduced susceptibility to zanamivir have been selected in cell culture by multiple passages of the virus in the presence of increasing concentrations of the drug. Reduced susceptibility of influenza virus to inhibition by zanamivir may be conferred by amino acid substitutions in the viral NA and/or hemagglutinin (HA) proteins (<linkHtml href="#_Reftable_6">Table 6</linkHtml>).</paragraph><table ID="_Reftable_6" width="99.02%"><caption>Table 6: Amino Acid Substitutions Selected by Zanamivir in Cell Culture Studies</caption><col width="12%"/><col width="29%"/><col width="29%"/><col width="30%"/><tfoot><tr><td align="left" colspan="4" styleCode="Botrule" valign="top"><sup>a</sup>  Numbering based on A/California/04/2009.<br/><sup>b</sup>  Numbering based on A/Texas/50/2012.<br/><sup>c</sup>  Numbering based on B/Massachusetts/02/2012.<br/><sup>d</sup>  HA numbering begins after the predicted signal peptide.</td></tr></tfoot><tbody><tr><td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Protein</content></paragraph></td><td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Type/Subtype</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H1N1<sup>a</sup></content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H3N2<sup>b</sup></content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">B<sup>c</sup></content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>NA</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>D199G</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>T148I</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph>E117D/G</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="bottom"><paragraph>HA<sup>d</sup></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="bottom"><paragraph>G155E, A197T</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="bottom"><paragraph>--</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="bottom"><paragraph>V90A, N145S, N150S, Q226K, L239Q</paragraph></td></tr></tbody></table><paragraph><content styleCode="italics">Clinical:</content> Influenza viruses with amino acid substitutions and deletions associated with reduced susceptibility to zanamivir have been identified in patients treated with zanamivir and in circulating viruses from untreated individuals. Genetic analysis of these viruses showed that the reduced susceptibility to zanamivir is associated with mutations that result in amino acid changes in the viral NA or viral HA or both (see <linkHtml href="#_Reftable_7">Table 7</linkHtml>). The clinical impact of substitutions that reduce virus susceptibility to zanamivir is variable and may be strain-dependent. </paragraph><table ID="_Reftable_7" width="100%"><caption>Table 7: Amino Acid Substitutions Observed in Virus from Humans and Associated with Reduced Susceptibility to Zanamivir</caption><col width="12%"/><col width="29%"/><col width="29%"/><col width="29%"/><tfoot><tr><td align="left" colspan="8" styleCode="Botrule" valign="top"><sup>a</sup>  Numbering based on A/California/04/2009.<br/><sup>b</sup>  Numbering based on A/Texas/50/2012.<br/><sup>c</sup>  Numbering based on B/Massachusetts/02/2012.<br/><sup>d</sup>  Emerged in patients treated with zanamivir.<br/><sup>e</sup>  HA numbering begins after the predicted signal peptide.</td></tr></tfoot><tbody><tr><td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Protein</content></paragraph></td><td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Type/Subtype</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H1N1<sup>a</sup></content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H3N2<sup>b</sup></content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">B<sup>c</sup></content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>NA</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>N70S, E119D<sup>d</sup>/G<sup>d</sup>/K<sup>d</sup>, H126N, Q136K, D151G+H275Y, Y155H, I223K/R<sup>d</sup>, S247I/R, G249R, I267V, Q313R, N325K, R368G<sup>d</sup> G370D<sup>d</sup>, I427T, N434S<sup>d</sup>, G460S</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Q136K, D151A/G/V, V165I+H274N, G248R+K249E, N294S<sup>d</sup>, T325I<sup>d</sup></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>G104E, E105K, T106L+P165L, H134N, Q138R, P139S, G140R, R150K<sup>d</sup>, K186R+I262T, D197E/Y, A200T, I221T<sup>d</sup>, G243S, A245T, S249G, R374K, G407S</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>HA<sup>e</sup></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>L151P<sup>d</sup>, V152I, S162N, S183P, A197T, D222G</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>R142G<sup>d</sup>, N225D</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>T198I<sup>d</sup></paragraph></td></tr></tbody></table><paragraph><content styleCode="italics">Zoonotic Viruses:</content> Substitutions conferring reduced susceptibility to zanamivir have been observed in viruses with zoonotic potential (<linkHtml href="#_Reftable_8">Table 8</linkHtml>). The clinical impact of reduced susceptibility in these viruses is unknown, and the effects of specific substitutions on virus susceptibility to zanamivir may be strain-dependent.</paragraph><table ID="_Reftable_8" width="100%"><caption>Table 8: Amino Acid Substitutions Observed in Avian Influenza Viruses with Zoonotic Potential and Associated with Reduced Susceptibility to Zanamivir</caption><col width="10%"/><col width="41%"/><col width="48%"/><tfoot><tr><td align="left" colspan="11" styleCode="Botrule" valign="top"><sup>a</sup>  Numbering based on A/Vietnam/1203/2004.<br/><sup>b</sup>  Numbering based on A/Anhui/1/2013.<br/><sup>c</sup>  Selected in cell culture or animal models of influenza.<br/><sup>d</sup>  Observed in virus isolated from humans.</td></tr></tfoot><tbody><tr><td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Protein</content></paragraph></td><td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Type/Subtype</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H5N1<sup>a</sup> (N2 numbering)</content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H7N9<sup>b </sup>(N2 numbering)</content></paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>NA</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>V96A (116), E99A/G<sup>c</sup> (119), Q116L<sup>c</sup> (136), V129A<sup>d</sup> (149), D179G (198)</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>E115V<sup>d</sup> (119), R148K<sup>d</sup> (152), I219K/R<sup>d</sup> (222), R289K<sup>d</sup> (292)</paragraph></td></tr></tbody></table><paragraph>Circulating resistant variants may change from season to season. Prescribers should consider available information from the U.S. Centers for Disease Control and Prevention regarding influenza virus drug susceptibility patterns and treatment effects when deciding whether to use zanamivir.</paragraph><paragraph><content styleCode="underline">Cross-Resistance</content></paragraph><paragraph>Cross-resistance between zanamivir and oseltamivir or peramivir has been observed in neuraminidase inhibition assays and cell culture assays. The NA amino acid substitutions that have been shown to result in reduced susceptibility to zanamivir and either oseltamivir or peramivir are summarized in <linkHtml href="#_Reftable_9">Table 9</linkHtml>. HA substitutions associated with reduced susceptibility to zanamivir may reduce susceptibility to all NAIs. The clinical impact of substitutions associated with reduced susceptibility to zanamivir and other NAIs is variable and may be strain-dependent.</paragraph><table ID="_Reftable_9" width="97%"><caption>Table 9: Summary of Neuraminidase Amino Acid Substitutions with Cross-Resistance between Zanamivir and Oseltamivir or Peramivir in Susceptibility Assays</caption><col width="19%"/><col width="25%"/><col width="25%"/><col width="32%"/><tfoot><tr><td align="left" colspan="15" styleCode="Botrule" valign="top"><sup>a</sup>  Numbering based on A/California/04/2009.<br/><sup>b</sup>  Numbering based on A/Texas/50/2012.<br/><sup>c</sup>  Numbering based on B/Massachusetts/02/2012.<br/><sup>d</sup>  Deletion of amino acids SASG.</td></tr></tfoot><tbody><tr><td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Neuraminidase Inhibitor</content></paragraph></td><td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"><paragraph><content styleCode="bold">Type/Subtype</content></paragraph></td></tr><tr><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H1N1<sup>a</sup></content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">A/H3N2<sup>b</sup></content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="bottom"><paragraph><content styleCode="bold">B<sup>c</sup></content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Oseltamivir</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>E119D/G, H126N, D151G+H275Y, R152K, Y155H, D199G, I223R/K, S247R, I267V, Q313R, N325K, R368K, I427T</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>E119I/V, D151V, ∆245-248<sup>d</sup>, R292K, N294S</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>G104E, E105K, E117D/G, P139S, G140R, R150K, D197E/N/Y, A200T, I221T, A245T, R374K, G407S</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Peramivir</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>E119D/G, H126N, Q136K, D151G+H275Y, D199G, I223R/K, S247R, I427T</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>E119I/V, Q136K, D151A/G/V, R292K</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>G104E, E105K, E117G, H134N, Q138R, P139S, G140R, D197E/N/Y, I221T, R374K, G407S</paragraph></td></tr></tbody></table><paragraph><content styleCode="underline">Influenza Vaccine Interaction Trial</content></paragraph><paragraph>An interaction trial (n = 138) was conducted to evaluate the effects of zanamivir (10 mg once daily) on the serological response to a single dose of trivalent inactivated influenza vaccine, as measured by hemagglutination inhibition titers. There was no difference in hemagglutination inhibition antibody titers at 2 weeks and 4 weeks after vaccine administration between zanamivir and placebo recipients.</paragraph></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_nonclinical_toxicology_id_67db4fe9-c98c-46e9-b462-5522f3857986"><id root="a8e1a304-a02b-4cfb-8f46-1e97bda77cc0"/><code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/><title>13 NONCLINICAL TOXICOLOGY</title><effectiveTime value="20180621"/><component><section ID="i4i_carcinogenesis_mutagenesis_fertility_id_fbfe4c03-2082-4ca0-921f-3b6493110968"><id root="37746976-a84e-447f-a3ab-5bd584dfd878"/><code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/><title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title><text><paragraph><content styleCode="underline">Carcinogenesis</content></paragraph><paragraph>In 2-year carcinogenicity studies conducted in rats and mice using a powder formulation administered through inhalation, zanamivir induced no statistically significant increases in tumors over controls. The maximum daily exposures in rats and mice were approximately 23 to 25 and 20 to 22 times, respectively, greater than those in humans at the proposed clinical dose based on AUC comparisons.</paragraph><paragraph><content styleCode="underline">Mutagenesis</content></paragraph><paragraph>Zanamivir was not mutagenic in in vitro and in vivo genotoxicity assays which included bacterial mutation assays in <content styleCode="italics">S. typhimurium</content> and <content styleCode="italics">E. coli</content>, mammalian mutation assays in mouse lymphoma, chromosomal aberration assays in human peripheral blood lymphocytes, and the in vivo mouse bone marrow micronucleus assay.</paragraph><paragraph><content styleCode="underline">Impairment of Fertility</content></paragraph><paragraph>Zanamivir did not impair mating or fertility of male or female rats and did not affect the sperm of treated male rats dosed for 10 weeks prior to mating and throughout mating, gestation/lactation, and shortly after weaning, and female rats dosed for 3 weeks prior to mating through organogenesis or lactation, at IV doses 1, 9, and 90 mg/kg/day, resulting in systemic drug exposures (AUC) estimated to be up to 300 times higher than the MRHID. </paragraph></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_clinical_studies_id_3b852be6-d013-4b15-8326-bc761c11ba12"><id root="e53fdffc-f41a-439c-921a-9cdbb77541c6"/><code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/><title>14 CLINICAL STUDIES</title><effectiveTime value="20180621"/><component><section ID="i4i_section_id_91a44324-678d-4752-8c32-73111782491a"><id root="c60e3e0a-5d62-4298-81e2-f5cb079576c4"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>14.1 Treatment of Influenza</title><text><paragraph><content styleCode="underline">Adults and Adolescents</content></paragraph><paragraph>The efficacy of PRODUCT A 10 mg inhaled twice daily for 5 days in the treatment of influenza has been evaluated in placebo-controlled trials conducted in North America, the Southern Hemisphere, and Europe during their respective influenza seasons. The magnitude of treatment effect varied between trials, with possible relationships to population-related factors including amount of symptomatic relief medication used.</paragraph><paragraph><content styleCode="italics">Populations Studied:</content> The principal Phase 3 trials enrolled 1,588 subjects aged 12 years and older (median age 34 years, 49% male, 91% Caucasian), with uncomplicated influenza-like illness within 2 days of symptom onset. Influenza was confirmed by culture, hemagglutination inhibition antibodies, or investigational direct tests. Of 1,164 subjects with confirmed influenza, 89% had influenza A and 11% had influenza B. These trials served as the principal basis for efficacy evaluation, with more limited Phase 2 studies providing supporting information where necessary. Following randomization to either zanamivir or placebo (inhaled lactose vehicle), all subjects received instruction and supervision by a healthcare professional for the initial dose.</paragraph><paragraph><content styleCode="italics">Principal Results:</content> The definition of time to improvement in major symptoms of influenza included no fever and self-assessment of “none” or “mild” for headache, myalgia, cough, and sore throat. A Phase 2 and a Phase 3 trial conducted in North America (total of over 600 influenza-positive subjects) suggested up to 1 day of shortening of median time to this defined improvement in symptoms in subjects receiving zanamivir compared with placebo, although statistical significance was not reached in either of these trials. In a trial conducted in the Southern Hemisphere (321 influenza-positive subjects), a 1.5-day difference in median time to symptom improvement was observed. Additional evidence of efficacy was provided by the European trial.</paragraph><paragraph><content styleCode="italics">Other Findings:</content> There was no consistent difference in treatment effect in subjects with influenza A compared with influenza B; however, these trials enrolled smaller numbers of subjects with influenza B and thus provided less evidence in support of efficacy in influenza B.</paragraph><paragraph>In general, subjects with lower temperature (e.g., 38.2°C or less) or investigator-rated as having less severe symptoms at entry derived less benefit from therapy.</paragraph><paragraph>No consistent treatment effect was demonstrated in subjects with underlying chronic medical conditions, including respiratory or cardiovascular disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_bae3af87-90c3-4fbc-aa38-97b62e5a9c60">5.4</linkHtml>)].</content></paragraph><paragraph>No consistent differences in rate of development of complications were observed between treatment groups.</paragraph><paragraph>Some fluctuation of symptoms was observed after the primary trial endpoint in both treatment groups.</paragraph><paragraph><content styleCode="underline">Pediatric Patients</content></paragraph><paragraph>The efficacy of PRODUCT A 10 mg inhaled twice daily for 5 days in the treatment of influenza in pediatric patients has been evaluated in a placebo-controlled trial conducted in North America and Europe, enrolling 471 subjects, aged 5 to 12 years (55% male, 90% Caucasian), within 36 hours of symptom onset. Of 346 subjects with confirmed influenza, 65% had influenza A and 35% had influenza B. The definition of time to improvement included no fever and parental assessment of no or mild cough and absent/minimal muscle and joint aches or pains, sore throat, chills/feverishness, and headache. Median time to symptom improvement was 1 day shorter in subjects receiving zanamivir compared with placebo. No consistent differences in rate of development of complications were observed between treatment groups. Some fluctuation of symptoms was observed after the primary trial endpoint in both treatment groups.</paragraph><paragraph>Although this trial was designed to enroll children aged 5 to 12 years, the product is indicated only for children aged 7 years and older. This evaluation is based on the combination of lower estimates of treatment effect in 5- and 6-year-olds compared with the overall trial population, and evidence of inadequate inhalation through the DISKHALER in a pharmacokinetic trial <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#i4i_pediatric_use_id_2f49ed46-aa35-4bb1-95ba-3641a5164d04">8.4</linkHtml>), Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_1d1feeae-4abe-476b-ad9f-42f65398336d">12.3</linkHtml>)]</content>.</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_section_id_58f0ac09-0968-446c-b72b-9d46d737f2b2"><id root="e6f52ab8-5637-44e8-8ed3-7d53072f9c01"/><code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/><title>14.2 Prophylaxis of Influenza</title><text><paragraph>The efficacy of PRODUCT A in preventing naturally occurring influenza illness has been demonstrated in 2 post-exposure prophylaxis trials in households and 2 seasonal prophylaxis trials during community outbreaks of influenza. The primary efficacy endpoint in these trials was the incidence of symptomatic, laboratory-confirmed influenza, defined as the presence of 2 or more of the following symptoms: oral temperature greater than or equal to 100°F/37.8°C or feverishness, cough, headache, sore throat, and myalgia; and laboratory confirmation of influenza A or B by culture, PCR, or seroconversion (defined as a 4-fold increase in convalescent antibody titer from baseline).</paragraph><paragraph><content styleCode="underline">Household Prophylaxis Trials</content></paragraph><paragraph>Two trials assessed post-exposure prophylaxis in household contacts of an index case. Within 1.5 days of onset of symptoms in an index case, each household (including all family members aged 5 years and older) was randomized to PRODUCT A 10 mg inhaled once daily or placebo inhaled once daily for 10 days. In the first trial only, each index case was randomized to PRODUCT A 10 mg inhaled twice daily for 5 days or inhaled placebo twice daily for 5 days. In this trial, the proportion of households with at least 1 new case of symptomatic laboratory-confirmed influenza was reduced from 19.0% (32 of 168 households) for the placebo group to 4.1% (7 of 169 households) for the group receiving PRODUCT A.</paragraph><paragraph>In the second trial, index cases were not treated. The incidence of symptomatic laboratory-confirmed influenza was reduced from 19.0% (46 of 242 households) for the placebo group to 4.1% (10 of 245 households) for the group receiving PRODUCT A.</paragraph><paragraph><content styleCode="underline">Seasonal Prophylaxis Trials</content></paragraph><paragraph>Two seasonal prophylaxis trials assessed PRODUCT A 10 mg inhaled once daily versus placebo inhaled once daily for 28 days during community outbreaks. The first trial enrolled subjects aged 18 years or older (mean age: 29 years) from 2 university communities. The majority of subjects were unvaccinated (86%). In this trial, the incidence of symptomatic laboratory-confirmed influenza was reduced from 6.1% (34 of 554) for the placebo group to 2.0% (11 of 553) for the group receiving PRODUCT A.</paragraph><paragraph>The second seasonal prophylaxis trial enrolled subjects aged 12 to 94 years (mean age: 60 years) with 56% of them older than 65 years. Sixty-seven percent of the subjects were vaccinated. In this trial, the incidence of symptomatic laboratory-confirmed influenza was reduced from 1.4% (23 of 1,685) for the placebo group to 0.2% (4 of 1,678) for the group receiving PRODUCT A.</paragraph></text><effectiveTime value="20180621"/></section></component></section></component><component><section ID="i4i_how_supplied_id_8af0c156-f6aa-4be6-b132-42f1799a8b61"><id root="afb52fc6-6e26-47b5-90f8-1d56aa28c1a5"/><code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/><title>16 HOW SUPPLIED/STORAGE AND HANDLING</title><text><paragraph>PRODUCT A is supplied in a circular double-foil pack (a ROTADISK) containing 4 blisters of the drug. Five ROTADISKs are packaged in a white polypropylene tube. The tube is packaged in a carton with 1 blue and gray DISKHALER inhalation device (NDC 0173-0681-01).</paragraph><paragraph><content styleCode="bold">Store at 25</content>°<content styleCode="bold">C (77</content>°<content styleCode="bold">F); excursions permitted to 15</content>°<content styleCode="bold"> to 30</content>°<content styleCode="bold">C (59</content>°<content styleCode="bold"> to 86</content>°<content styleCode="bold">F) (see USP Controlled Room Temperature). </content>Keep out of reach of children. Do not puncture any PRODUCT A ROTADISK blister until taking a dose using the DISKHALER.</paragraph></text><effectiveTime value="20131017"/></section></component><component><section ID="i4i_info_patients_id_c146070e-3dcb-479d-8314-45aa492924bd"><id root="dd5ffe1a-2ce2-4ea6-869e-2e2e8deb69e0"/><code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/><title>17 PATIENT COUNSELING INFORMATION</title><text><paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph><paragraph><content styleCode="underline">Bronchospasm</content></paragraph><paragraph><content styleCode="bold">Inform patients of the risk of bronchospasm, especially in the setting of underlying airways disease, and advise patients to stop PRODUCT A and contact their healthcare provider if they experience increased respiratory symptoms during treatment such as worsening wheezing, shortness of breath, or other signs or symptoms of bronchospasm <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_afe28a86-13b1-43e9-a0cb-25da5ba4c6ad">5.1</linkHtml>)]</content>. If a decision is made to prescribe PRODUCT A for a patient with asthma or chronic obstructive pulmonary disease, the patient should be made aware of the risks and should have a fast-acting bronchodilator available.</content></paragraph><paragraph><content styleCode="underline">Concomitant Bronchodilator Use</content></paragraph><paragraph>Patients scheduled to take inhaled bronchodilators at the same time as PRODUCT A should be advised to use their bronchodilators before taking PRODUCT A.</paragraph><paragraph><content styleCode="underline">Neuropsychiatric Events</content></paragraph><paragraph>Inform patients with influenza (the flu), particularly children and adolescents, they may be at an increased risk of seizures, confusion, or abnormal behavior early in their illness. These events may occur after beginning PRODUCT A or may occur when flu is not treated. These events are uncommon but may result in accidental injury to the patient. Therefore, patients should be observed for signs of unusual behavior and a healthcare professional should be contacted immediately if the patient shows any signs of unusual behavior <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_3de8b6a5-8f12-4b25-a8d2-95169f34b8e6">5.3</linkHtml>)]</content>.</paragraph><paragraph><content styleCode="underline">Risk of Influenza Transmission to Others</content></paragraph><paragraph>Inform patients that the use of PRODUCT A for treatment of influenza has not been shown to reduce the risk of transmission of influenza to others.</paragraph><paragraph><content styleCode="underline">Missed Dose</content></paragraph><paragraph>Instruct patients that if they miss a dose of PRODUCT A, to take it as soon as they remember. If it is 2 hours or less before their next dose, instruct patients not to take the missed dose and to take the next dose of PRODUCT A at the next scheduled time. Advise patients not to double their next dose or take more than the prescribed dose.</paragraph><paragraph><content styleCode="underline">Instructions for Use</content></paragraph><paragraph>Instruct patients in use of the delivery system. Instructions should include a demonstration whenever possible. For the proper use of PRODUCT A, the patient should read and follow carefully the accompanying Instructions for Use.</paragraph><paragraph><content styleCode="bold">If PRODUCT A is prescribed for children, it should be used only under adult supervision and instruction, and the supervising adult should first be instructed by a healthcare professional <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#i4i_section_id_b970323a-5dc5-4466-afb7-b2a15078d07d">2.1</linkHtml>)]</content>.</content></paragraph><paragraph>Trademarks are owned by or licensed to the MAH-A group of companies.</paragraph><paragraph>MAH-A</paragraph><paragraph> Rsearch, NC 27709</paragraph><paragraph>©2018 MAH-A group of companies or its licensor.</paragraph><paragraph>RLZ: 12PI</paragraph></text><effectiveTime value="20180621"/></section></component><component><section ID="i4i_patient_package_insert_id_a81b3abe-dc1f-4e0c-b8c7-9e934211fe13"><id root="189650fd-88e1-4250-a269-9dadf41438d3"/><code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/><text><table width="100%"><col width="4%"/><col width="48%"/><col width="48%"/><tbody><tr><td align="center" colspan="3" styleCode="Rrule Lrule Toprule " valign="middle"><paragraph><content styleCode="bold">PATIENT INFORMATION</content></paragraph></td></tr><tr><td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">PRODUCT A </content>(ruh-LENS-uh)</paragraph><paragraph><content styleCode="bold">(zanamivir inhalation powder)</content></paragraph><paragraph><content styleCode="bold">for oral inhalation use</content></paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">What is PRODUCT A?</content></paragraph><paragraph>PRODUCT A is a prescription medicine used to:</paragraph><list listType="unordered"><item><caption>•</caption>treat the flu (influenza A and B virus) in people who are aged 7 years and older who have had flu symptoms for no more than 2 days.</item><item><caption>•</caption>help prevent the flu in people who are aged 5 years and older.</item></list><paragraph>PRODUCT A is not recommended for the treatment or prevention of the flu in people with breathing problems, such as asthma and chronic obstructive pulmonary disease (COPD). </paragraph><paragraph>PRODUCT A does not treat or prevent illness that is caused by infections other than the influenza virus (A and B).</paragraph><paragraph>Using PRODUCT A for the treatment of the flu has not been shown to reduce the risk of spreading the flu to others.</paragraph><paragraph>It is not known if PRODUCT A is:</paragraph><list listType="unordered"><item><caption>•</caption>effective for the treatment of flu in people with breathing problems.</item><item><caption>•</caption>effective for the prevention of flu in people who live in nursing homes.</item><item><caption>•</caption>safe and effective for the treatment of flu in children younger than 7 years.</item><item><caption>•</caption>safe and effective for the prevention of flu in children younger than 5 years.</item></list><paragraph><content styleCode="bold">PRODUCT A does not take the place of receiving a flu vaccination. Talk to your healthcare provider about when you should receive an annual flu vaccination.</content></paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Do not take PRODUCT A if you</content> are allergic to zanamivir or any other ingredient of PRODUCT A, including milk proteins. See the end of this Patient Information leaflet for a complete list of ingredients in PRODUCT A.</paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Before taking PRODUCT A, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType="unordered"><item><caption>•</caption>have any breathing problems, such as asthma or COPD.</item><item><caption>•</caption>received live attenuated influenza vaccine (LAIV) in your nose (intranasal) in the past 2 weeks.</item><item><caption>•</caption>are pregnant or plan to become pregnant. </item><item><caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if PRODUCT A passes into your breast milk.</item></list><paragraph><content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">How should I take PRODUCT A?</content></paragraph><paragraph><content styleCode="bold">Read the Instructions for Use at the end of this Patient Information for detailed information on how to take PRODUCT A.</content></paragraph><list listType="unordered"><item><caption>•</caption>Take PRODUCT A exactly as your healthcare provider tells you to.</item><item><caption>•</caption>PRODUCT A is taken by oral inhalation using a DISKHALER.</item><item><caption>•</caption>If you are scheduled to use an inhaled bronchodilator at the same time as PRODUCT A, use the inhaled bronchodilator <content styleCode="bold">before</content> taking PRODUCT A.</item><item><caption>•</caption>Each dose of PRODUCT A requires 2 inhalations. Each inhalation requires 1 blister.</item></list><paragraph><content styleCode="bold">For the treatment of flu in people aged 7 years and older, take PRODUCT A as follows:</content></paragraph><list listType="unordered"><item><caption>•</caption>Take each dose of PRODUCT A as 2 inhalations (use 1 blister per inhalation) 2 times a day for 5 days.</item><item><caption>•</caption>On the first day, wait at least <content styleCode="underline">2 hours</content> between each dose. </item><item><caption>•</caption>Starting on the second day, wait at least <content styleCode="underline">12 hours</content> between each dose.</item></list><paragraph><content styleCode="bold">To help prevent the flu in people aged 5 years and older, take PRODUCT A as follows:</content></paragraph><list listType="unordered"><item><caption>•</caption>Take each dose of PRODUCT A as 2 inhalations (use 1 blister per inhalation) 1 time each day for 10 or 28 days as prescribed by your healthcare provider.</item><item><caption>•</caption>Take PRODUCT A at the same time each day. </item></list><paragraph>If you miss a dose of PRODUCT A, take it as soon as you remember. If it is 2 hours or less before your next dose, do not take the missed dose. Take your next dose of PRODUCT A at your scheduled time. Do not take 2 doses at the same time. </paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">What are the possible side effects of PRODUCT A?</content></paragraph><paragraph><content styleCode="bold">PRODUCT A can cause serious side effects, including:</content></paragraph><list listType="unordered"><item><caption>•</caption><content styleCode="bold">Bronchospasm (wheezing).</content> Serious breathing problems, including death, have happened during treatment with PRODUCT A in people with and without a history of breathing problems. 41TStop taking PRODUCT A and get emergency medical help right away if you develop:</item></list></td></tr><tr><td styleCode="Lrule " valign="top"/><td valign="top"><list listType="unordered"><item><caption>•</caption>worsening breathing</item><item><caption>•</caption>shortness of breath</item></list></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>chest pain or tightness</item><item><caption>•</caption>cough</item></list></td></tr><tr><td colspan="3" styleCode="Rrule Lrule " valign="top"><list listType="unordered"><item><caption>•</caption>If you have breathing problems, such as asthma and COPD and your healthcare provider has prescribed PRODUCT A, you should have a fast‑acting, inhaled bronchodilator available for your use. See <content styleCode="bold">“How should I take PRODUCT A?”</content></item><item><caption>•</caption><content styleCode="bold">Serious allergic reactions.</content> PRODUCT A can cause serious allergic reactions. Stop taking PRODUCT A and get emergency medical help right away if you get any of the following symptoms:</item></list></td></tr><tr><td styleCode="Lrule " valign="top"/><td valign="top"><list listType="unordered"><item><caption>•</caption>skin rash or hives</item><item><caption>•</caption>your skin blisters and peels</item><item><caption>•</caption>blisters or sores in your mouth</item><item><caption>•</caption>itching</item></list></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>swelling of your face, eyes, lips, tongue, or throat</item><item><caption>•</caption>trouble breathing</item><item><caption>•</caption>chest pain or tightness</item></list></td></tr><tr><td colspan="3" styleCode="Rrule Lrule " valign="top"><list listType="unordered"><item><caption>•</caption><content styleCode="bold">Change in behavior</content>. People, especially children, who have the flu, can develop nervous system problems and abnormal behavior that can lead to death. During treatment with PRODUCT A, tell your healthcare provider right away if you or your child have confusion, speech problems, shaky movements, seizures, or start hearing voices or seeing things that are not really there (hallucinations).</item></list><paragraph><content styleCode="bold">The most common side effects of PRODUCT A include:</content></paragraph></td></tr><tr><td styleCode="Lrule " valign="top"/><td valign="top"><list listType="unordered"><item><caption>•</caption>headaches</item><item><caption>•</caption>diarrhea</item><item><caption>•</caption>nausea</item><item><caption>•</caption>vomiting</item><item><caption>•</caption>irritation of the nose</item></list></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>airway irritation (bronchitis)</item><item><caption>•</caption>cough</item><item><caption>•</caption>sinusitis</item><item><caption>•</caption>ear, nose, and throat infections</item><item><caption>•</caption>dizziness</item></list></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Other kinds of infections can appear like flu or happen along with flu, and may need different kinds of treatment. Call your healthcare provider if you feel worse or develop new symptoms during or after treatment with PRODUCT A, or if your flu symptoms do not start to get better.</paragraph><paragraph>These are not all of the possible side effects of PRODUCT A. </paragraph><paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.</paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">How should I store PRODUCT A?</content></paragraph><list listType="unordered"><item><caption>•</caption>Store PRODUCT A at room temperature below 77°F (25°C).</item><item><caption>•</caption>Do not puncture any PRODUCT A ROTADISK blister until you are ready to take your dose using the DISKHALER.</item></list><paragraph><content styleCode="bold">Keep PRODUCT A and all medicines out of the reach of children.</content></paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">General information about the safe and effective use of PRODUCT A.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PRODUCT A for a condition for which it was not prescribed. Do not give PRODUCT A to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about PRODUCT A that is written for health professionals.</paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">What are the ingredients in PRODUCT A?</content></paragraph><paragraph>Active ingredient: zanamivir</paragraph><paragraph>Inactive ingredients: lactose (which contains milk proteins)</paragraph></td></tr><tr><td colspan="3" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>MAH-A</paragraph><paragraph> Rsearch, NC 27709</paragraph><paragraph>PRODUCT A, ROTADISK, and DISKHALER are trademarks owned by or licensed to the MAH-A group of companies.</paragraph><paragraph>©2018 the MAH-A group of companies or its licensor.</paragraph><paragraph>RLZ:8PIL</paragraph><paragraph>For more information call -1-888-825-5249.</paragraph></td></tr><tr><td colspan="2" styleCode="Botrule " valign="top"><paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration. </paragraph></td><td styleCode="Botrule " valign="top"><paragraph>Revised: 06/2018</paragraph></td></tr></tbody></table><table width="100%"><col width="51%"/><col width="49%"/><tbody><tr><td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="middle"><paragraph><content styleCode="bold">INSTRUCTIONS FOR USE</content><br/><content styleCode="bold">PRODUCT A</content> (ruh-LENS-uh)<br/><content styleCode="bold">(zanamivir inhalation powder)</content><br/><content styleCode="bold">for oral inhalation use</content></paragraph></td></tr><tr><td colspan="2" styleCode="Rrule Lrule " valign="middle"><paragraph><content styleCode="bold">Read the Patient Information and this Instructions for Use before you start using PRODUCT A.</content></paragraph><paragraph><content styleCode="bold">Important information:</content></paragraph><list listType="unordered"><item><caption>•</caption><content styleCode="bold">Be sure to take the dose of PRODUCT A your healthcare provider has prescribed. </content></item><item><caption>•</caption><content styleCode="bold">If PRODUCT A is prescribed for a child, the dose should be given or supervised by an adult who has been instructed on how to use the DISKHALER the right way by a healthcare provider and understands how to use it.</content></item><item><caption>•</caption>Always check inside the mouthpiece to make sure it is clear before each use. If foreign objects are in the mouthpiece, they could be inhaled and cause serious harm.</item><item><caption>•</caption>Always replace the cover after each use.</item><item><caption>•</caption>Throw away the DISKHALER after treatment is completed.</item><item><caption>•</caption>PRODUCT A is not in a child-proof container.</item></list></td></tr><tr><td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle"><renderMultiMedia ID="id-1156445185" referencedObject="ID_3529da9e-857e-47e7-9d3e-36f4678f6584"/><paragraph><content styleCode="bold">Step-by-step instructions for using the DISKHALER:</content></paragraph></td></tr><tr><td colspan="2" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Step 1: Load the medicine into the DISKHALER.</content></paragraph></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id1566769599" referencedObject="ID_0e911030-e6cf-4678-abf4-928c929a2029"/><paragraph><content styleCode="bold">Figure A</content></paragraph></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>Start by pulling off the blue cover. <content styleCode="bold">See Figure A</content>.</item><item><caption>•</caption><content styleCode="bold">Always check inside the mouthpiece to make sure it is clear before each use. If foreign objects are in the mouthpiece, they could be inhaled and cause serious harm.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id-400451719" referencedObject="ID_5c51c394-3fe6-42f8-b097-b822925d21f8"/><paragraph><content styleCode="bold">Figure B</content></paragraph></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>Pull the white mouthpiece by the edges to extend the white tray all the way. <content styleCode="bold">See Figure B.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id-695471792" referencedObject="ID_95283b5e-3181-44a0-8fb4-dc65e3bb44c1"/><paragraph><content styleCode="bold">Figure C</content></paragraph></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>Once the white tray is extended all the way, find the raised ridges on each side of it. Press in these ridges, both sides at the same time, and <content styleCode="bold">pull the whole white tray out of the DISKHALER body</content>. <content styleCode="bold">See Figure C.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id2143697266" referencedObject="ID_2e6bcb4e-f67b-44d1-b1bb-4a92b09e1d17"/><paragraph><content styleCode="bold">Figure D</content></paragraph></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>Place one silver medicine disk onto the dark brown wheel, flat side up. The four silver blisters on the underside of the medicine disk will drop neatly into the four holes in the wheel. <content styleCode="bold">See Figure D.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule Botrule " valign="top"><renderMultiMedia ID="id-267232010" referencedObject="ID_858cb075-59b2-428d-985e-896e5a93464a"/><paragraph><content styleCode="bold">Figure E</content></paragraph></td><td styleCode="Rrule Botrule " valign="top"><list listType="unordered"><item><caption>•</caption>Push in the white tray as far as it will go. Now the DISKHALER is loaded with medicine. <content styleCode="bold">See Figure E.</content></item></list></td></tr><tr><td colspan="2" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Step 2: Puncture the blister.</content><br/><br/><content styleCode="bold">The DISKHALER punctures 1 blister of medicine at a time so you can inhale the right amount. It does not matter which blister you start with. Check to make sure that the silver foil is not broken.</content></paragraph></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id374358621" referencedObject="ID_7c650c3d-f0d1-4a83-98d1-381d2d67ee44"/><list listType="unordered"><item><caption> </caption><content styleCode="bold">Figure F</content></item></list></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>Be sure to keep the DISKHALER level so the medicine does not spill out.<content styleCode="bold"> See Figure F.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id-1445078807" referencedObject="C74861B7-4784-4D4B-89A9-EF9D6A5634BF"/><paragraph><content styleCode="bold">Figure G</content></paragraph></td><td styleCode="Rrule " valign="top"><list listType="unordered"><item><caption>•</caption>Locate the half-circle flap with the name “PRODUCT A” on top of the DISKHALER.</item><item><caption>•</caption>Lift this flap from the outer edge until it cannot go any farther. Flap must be <content styleCode="bold">straight up</content> for the plastic needle to puncture both the <content styleCode="bold">top</content> and <content styleCode="bold">bottom</content> of the silver medicine disk inside. <content styleCode="bold">See Figure G.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule Botrule " valign="top"><renderMultiMedia ID="id2037077267" referencedObject="ID_0a381525-0bdb-4121-9307-c192c3b70d63"/><paragraph><content styleCode="bold">Figure H</content></paragraph></td><td styleCode="Rrule Botrule " valign="top"><list listType="unordered"><item><caption>•</caption>Keeping the DISKHALER level, click the flap down into place. <content styleCode="bold">See Figure H.</content></item></list></td></tr><tr><td colspan="2" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Step 3: Inhale.</content></paragraph></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id1201823911" referencedObject="ID_9bc6b70a-5dfc-4d43-a33d-61e4328ad45e"/><paragraph><content styleCode="bold">Figure I</content></paragraph></td><td rowspan="2" styleCode="Rrule Botrule " valign="top"><list listType="unordered"><item><caption>•</caption>Before putting the white mouthpiece into your mouth, breathe all the way out (exhale). <content styleCode="bold">See Figure I.</content></item><item><caption> </caption><content styleCode="bold">Then put the white mouthpiece into your mouth. Be sure to keep the DISKHALER level so the medicine does not spill out.</content></item><item><caption>•</caption>Close your lips firmly around the mouthpiece. Be sure not to cover the small holes on either side of it. <content styleCode="bold">See Figure J.</content></item><item><caption>•</caption>Breathe in through your mouth steadily and as deeply as you can. Your breath pulls the medicine into your airways and lungs.</item><item><caption>•</caption>Hold your breath for a few seconds to help PRODUCT A stay in your lungs where it can work.</item></list></td></tr><tr><td align="center" styleCode="Lrule Botrule " valign="top"><renderMultiMedia ID="id-1393417636" referencedObject="C6D02A50-6AE7-47AA-8E5C-D99C275E6FF4"/><paragraph><content styleCode="bold">Figure J</content></paragraph></td></tr><tr><td colspan="2" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">To take another inhalation, move to the next blister by following Step 4 below.</content></paragraph><paragraph><content styleCode="bold">After you have inhaled the number of blisters prescribed by your healthcare provider, replace the cover until your next dose.</content></paragraph></td></tr><tr><td colspan="2" styleCode="Rrule Lrule " valign="top"><paragraph><content styleCode="bold">Step 4: Move the medicine disk to the next blister.</content></paragraph></td></tr><tr><td align="center" styleCode="Lrule " valign="top"><renderMultiMedia ID="id924303542" referencedObject="CDD08C43-6BE9-4EBA-9A16-CAF0F6FDCE3B"/><paragraph><content styleCode="bold">Figure K</content></paragraph></td><td styleCode="Rrule " valign="middle"><list listType="unordered"><item><caption>•</caption>Pull the mouthpiece to extend the white tray, without removing it. <content styleCode="bold">See Figure K.</content></item></list></td></tr><tr><td align="center" styleCode="Lrule Botrule " valign="top"><renderMultiMedia ID="id-1461418543" referencedObject="ID_7fd30860-7e51-44bc-a736-8c7e2ea9f0fd"/><paragraph><content styleCode="bold">Figure L</content></paragraph></td><td styleCode="Rrule Botrule " valign="top"><list listType="unordered"><item><caption>•</caption>Then <content styleCode="bold">push </content>it back until it clicks. This pull-push motion rotates the medicine disk to the next blister. <content styleCode="bold">See Figure L.</content></item><item><caption>•</caption>To take your next inhalation, repeat Steps 2 and 3.</item></list></td></tr><tr><td colspan="2" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">If all 4 blisters in the medicine disk have been used, you are ready to start a new medicine disk (see Step 1). Check to make sure that the silver foil is not broken each time you are ready to puncture the next blister.</content></paragraph></td></tr><tr><td colspan="2" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>PRODUCT A and DISKHALER are trademarks owned by or licensed to the MAH-A group of companies. <br/><br/>MAH-A</paragraph><paragraph> Rsearch, NC 27709</paragraph><paragraph>©2018 MAH-A group of companies or its licensor. </paragraph><paragraph>Revised: 06/2018</paragraph><paragraph>RLZ:1IFU</paragraph></td></tr></tbody></table><paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. <br/><br/></paragraph></text><effectiveTime value="20180621"/><component><observationMedia ID="ID_3529da9e-857e-47e7-9d3e-36f4678f6584"><text>Parts of the DISKHALER</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-02.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_0e911030-e6cf-4678-abf4-928c929a2029"><text>Figure A</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-03.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_5c51c394-3fe6-42f8-b097-b822925d21f8"><text>Figure B</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-04.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_95283b5e-3181-44a0-8fb4-dc65e3bb44c1"><text>Figure C</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-05.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_2e6bcb4e-f67b-44d1-b1bb-4a92b09e1d17"><text>Figure D</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-06.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_858cb075-59b2-428d-985e-896e5a93464a"><text>Figure E</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-07.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_7c650c3d-f0d1-4a83-98d1-381d2d67ee44"><text>Figure F</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-08.jpg"/></value></observationMedia></component><component><observationMedia ID="C74861B7-4784-4D4B-89A9-EF9D6A5634BF"><text>Figure G</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-09.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_0a381525-0bdb-4121-9307-c192c3b70d63"><text>Figure H</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-10.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_9bc6b70a-5dfc-4d43-a33d-61e4328ad45e"><text>Figure I</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-11.jpg"/></value></observationMedia></component><component><observationMedia ID="C6D02A50-6AE7-47AA-8E5C-D99C275E6FF4"><text>Figure J</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-12.jpg"/></value></observationMedia></component><component><observationMedia ID="CDD08C43-6BE9-4EBA-9A16-CAF0F6FDCE3B"><text>Figure K</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-13.jpg"/></value></observationMedia></component><component><observationMedia ID="ID_7fd30860-7e51-44bc-a736-8c7e2ea9f0fd"><text>Figure L</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-14.jpg"/></value></observationMedia></component></section></component><component><section ID="i4i_Principal_display_panel_id_84b696dd-b9ba-4b71-a492-9e495220a184"><id root="6b883d25-85a2-4be0-9c59-76dc7eb4e464"/><code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/><text><paragraph><content styleCode="bold">PRINCIPAL DISPLAY PANEL</content></paragraph><paragraph><content styleCode="bold">NDC 0173-0681-01</content></paragraph><paragraph><content styleCode="bold">PRODUCT A</content></paragraph><paragraph><content styleCode="bold">(ZANAMIVIR) INHALATION POWDER</content></paragraph><paragraph><content styleCode="bold">20 mg per Rotadisk </content></paragraph><paragraph><content styleCode="bold">(5 mg per blister)</content></paragraph><paragraph>Each blister contains 5 mg zanamivir with lactose. </paragraph><paragraph>Use PRODUCT A with DISKHALER inhalation device only.</paragraph><paragraph>See enclosed “Patient Information” and “Patient Instructions for Use.”</paragraph><paragraph>Store at 25<sup>o</sup>C (77<sup>o</sup>F); excursions permitted to 15<sup>o</sup> to 30<sup>o</sup>C (59<sup>o</sup> to 86<sup>o</sup>F) (see USP Controlled Room Temperature). </paragraph><paragraph>Contains 5 PRODUCT A ROTADISKS<sup>®</sup> each containing four 5-mg blisters and one DISKHALER inhalation device.</paragraph><paragraph><content styleCode="bold">R<sub>x</sub> only</content></paragraph><paragraph>See prescribing information for dosage information. </paragraph><paragraph><content styleCode="bold">20 blisters</content></paragraph><paragraph><content styleCode="bold">FOR ORAL INHALATION ONLY</content></paragraph><paragraph>Made in UK</paragraph><paragraph>©2020 the MAH-A group of companies</paragraph><paragraph>Rev. 2/20</paragraph><paragraph>62000000045728</paragraph><renderMultiMedia ID="id646789438" referencedObject="ID_77b8a986-edb8-45d1-acb2-0a1994cf8ead"/></text><effectiveTime value="20180621"/><component><observationMedia ID="ID_77b8a986-edb8-45d1-acb2-0a1994cf8ead"><text>PRODUCT A carton</text><value mediaType="image/jpeg" xsi:type="ED"><reference value="product-a-spl-graphic-15.jpg"/></value></observationMedia></component></section></component></structuredBody></component></document>
